Finland – Pharmaceutical products – Monoclonal antibodies for the period 1.1.-31.12.2027 + option year 2028 for the welfare region of North Ostrobothnia
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Contract Description
The object of acquisition are monoclonal antibodies and antibody-conjugated drugs belonging to ATC group L01F. Offered medicinal products must have a marketing authorization in Finland and must be available for sale and available in Finland on January 1, 2027. The procurement also applies to medicinal products for which the marketing authorization process, parallel import authorization or parallel distribution notification process is in progress, but the marketing authorization or parallel import authorization is granted or the parallel distribution notification is accepted before the start of the procurement period and the products are sold and available in Finland no later than January 1, 2027. Anticipated procurement